Mutant hERα Tryptophan Phenylalanine Mutation Drug Discovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The lack of understanding of the architectural structure and domain interactions of estrogen receptor alpha (ERα) hinders the development of effective therapeutic agents for ERα-positive breast cancer, as current treatments like tamoxifen can lead to resistance over time.
Innovation Solution
A genetically engineered mutant human estrogen receptor alpha (hERα) with specific tryptophan residues mutated to phenylalanine is used to assess the effect of therapeutic agents on transcription regulation, providing a new target for drug discovery by characterizing the DBD-LBD interface and its allosteric function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tamoxifen is used as treatment for ERα-positive breast cancer, then initial treatment efficacy is achieved, but resistance develops over time
Solution Approach 1:
The patent mutates specific tryptophan residues (W383, W393, W481, W489) to phenylalanine in the ERα LBD, fundamentally changing the structural and functional parameters of the receptor. This creates a mutant ERα with altered allosteric communication properties between DBD and LBD, making it sensitive to new therapeutic agents while maintaining responsiveness to estrogen signaling, thereby overcoming tamoxifen resistance
Solution Approach 2:
The patent divides the ERα protein into functional domains (DBD and LBD) and specifically targets the interface between these segments. By mutating tryptophan residues at the DBD-LBD interface, the invention segments the allosteric communication pathway, allowing independent modulation of different functional aspects of the receptor through targeted therapeutic agents
2Loss of information
If the architectural structure and domain interactions of ERα are not understood, then drug development is hindered, but structural characterization requires complex experimental approaches
Solution Approach 1:
The patent uses tryptophan residues as intrinsic fluorescent probes that serve as intermediaries to report on conformational changes and domain interactions in real-time. These tryptophan fluorophores act as built-in sensors that mediate the detection of allosteric communication between DBD and LBD, eliminating the need for external labels or complex imaging equipment
Solution Approach 2:
The patent replaces complex structural biology techniques (such as cryo-EM or X-ray crystallography) with a biochemical fluorescence assay based on tryptophan emission. This substitution transforms a mechanically complex structural determination problem into a simpler optical measurement that can be performed in solution, dramatically reducing experimental complexity while providing dynamic functional information
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of therapeutic agents that target the mutant hERα, potentially overcoming resistance issues and improving treatment efficacy for ERα-positive breast cancer.
Implementation Method 1
A Genetically-Engineered Fluorescence Assay for Structure-Based Drug Discovery of Next-Generation Estrogen Receptor Inhibitors
Data Source
AI summary
One aspect of the present disclosure relates to an isolated mutant human estrogen receptor alpha (hERα) that may be used in methods of drug discovery. The isolated mutant hERα can include a DNA-binding domain (DBD), a ligand-binding domain (LBD), and an interface between the DBD and the LBD, wherein at least one tryptophan residue is mutated to a phenylalanine residue.